益盛药业(002566) - 2019 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2019 was ¥244,687,559.79, a decrease of 4.88% compared to ¥257,252,802.51 in the same period last year[7] - Net profit attributable to shareholders was ¥16,871,558.99, down 17.12% from ¥20,356,803.01 year-on-year[7] - Basic earnings per share decreased by 17.07% to ¥0.0510 from ¥0.0615 in the same period last year[7] - The company's net profit margin for Q1 2019 was approximately 8.9%, reflecting a decrease from the previous year's margin[35] - The net profit for Q1 2019 was CNY 19,746,399.38, down from CNY 27,034,290.09 in Q1 2018, indicating a decline of about 26.7%[38] - The total profit for Q1 2019 was CNY 22,831,521.01, a decrease from CNY 32,139,428.36 in the previous year, marking a decline of about 29.0%[38] - The company's operating profit for Q1 2019 was CNY 23,355,685.80, down from CNY 32,165,050.97 in Q1 2018, representing a decrease of approximately 27.4%[38] - The total comprehensive income for Q1 2019 was CNY 19,746,399.38, compared to CNY 27,034,290.09 in Q1 2018, showing a decrease of approximately 26.7%[38] Cash Flow and Financial Position - The net cash flow from operating activities increased significantly by 322.08%, reaching ¥72,102,073.45 compared to ¥17,082,514.28 in the previous year[7] - Cash and cash equivalents increased by 594.35% to ¥64,827,945.40, primarily due to a net increase in cash flow from operating activities[17] - Cash inflow from operating activities increased to CNY 259,524,460.60 for the current period[44] - The net cash flow from operating activities for Q1 2019 was CNY 58,126,696.50, a significant increase from CNY 13,917,625.96 in the same period last year, representing a growth of approximately 317%[49] - Cash outflow from operating activities decreased to CNY 156,228,047.83 from CNY 201,255,086.10, indicating improved operational efficiency[49] - The ending balance of cash and cash equivalents was CNY 78,944,907.78, up from CNY 62,895,602.06, reflecting a net increase of CNY 16,049,305.72[50] - The company received CNY 200,000,000.00 in borrowings during the quarter, which was fully utilized for debt repayment[50] - The cash flow from investment activities was negative at CNY -2,390,312.62, an improvement from CNY -4,913,155.81 in the previous year[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,611,298,935.37, reflecting a 2.28% increase from ¥2,553,101,177.99 at the end of the previous year[7] - Total liabilities increased to CNY 709,131,407.06 from CNY 672,108,262.11, reflecting a growth of 5.5%[34] - The total equity attributable to shareholders reached CNY 1,869,021,245.09, up from CNY 1,857,269,037.40, a rise of 0.9%[34] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[11] - Short-term borrowings remained stable at ¥430,000,000.00[27] Expenses and Impairments - The company reported a 233.39% increase in asset impairment losses to ¥2,862,200.63, primarily due to increased bad debt provisions[17] - Research and development expenses for Q1 2019 were CNY 3,451,674.58, compared to CNY 3,235,002.00 in the previous year, indicating an increase of 6.7%[35] - The company reported a significant increase in tax expenses, which rose to CNY 5,484,921.39 from CNY 2,795,937.38, a jump of 96.5%[35] - Tax expenses decreased by 39.57% to ¥3,085,121.63, resulting from a decrease in pre-tax profit due to lower subsidiary income[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,791[11] - The company did not report any non-operating fund occupation by controlling shareholders or related parties during the reporting period[21] - There were no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[19] Operational Performance - Total operating revenue for Q1 2019 was CNY 244,687,559.79, a decrease of 4.6% compared to CNY 257,252,802.51 in the same period last year[35] - Total operating costs for Q1 2019 were CNY 222,899,563.63, down 1.4% from CNY 226,507,488.26 in Q1 2018[35] - The company's operating income for Q1 2019 was CNY 197,717,981.06, an increase from CNY 188,691,938.07 in the same period last year, representing a growth of approximately 0.54%[40] - The total operating costs for Q1 2019 were CNY 40,055,637.92, compared to CNY 36,644,341.00 in Q1 2018, reflecting an increase of about 11.0%[40] Other Information - The company received government subsidies amounting to ¥1,386,384.23 during the reporting period[8] - The company did not report any significant new product launches or technological advancements during this quarter[51]